Backed by
Investors and funders behind Koios.
Koios reads the everyday signal of life with Parkinson’s and turns the noise into something steady — objective measures, every day, not just at the clinic.
Neurology runs on snapshots: a short exam, a questionnaire, and a patient trying to recall how a hard month felt. But symptoms shift hour to hour, and quality of life is difficult to capture in a fifteen-minute appointment.
So medication gets adjusted slowly, decline shows up late, and no one can measure whether care is working. Koios covers that gap — turning the time between visits into objective data that patients and clinicians can act on.
No clinic-grade hardware. No clunky wearables. No daily diary to fill in. Just the phone and smartwatch people already own.
A smartphone and a smartwatch. Parkiwatch runs quietly in the background — no tasks to complete, no change to daily routine.
Wrist movement becomes three validated kinematic measures — tremor, bradykinesia and dyskinesia — alongside supportive digital health measures.
Measures reach your healthcare professional via a dashboard and PDF reports, between clinic visits.
Parkiwatch is a Class IIa Software as a Medical Device (EU MDR 2017/745) intended for the continuous, passive detection and quantitative assessment of kinematic patterns representative of tremor, bradykinesia and dyskinesia in adults with Parkinson’s Disease. It does not diagnose Parkinson’s Disease, does not recommend or change your medication, and does not replace the judgment of your healthcare professional.
Take Parkiwatch home and arrive at every appointment with objective data instead of trying to remember how the month went. See your own patterns, and feel more in control.
Remote monitoring that fits your workflow. Validated kinematic measures between clinic visits, to ground each conversation in real-world data — all from one dashboard.
For clinicians & hospitals → For pharmaDecentralised trials with real-world measures of quality of life and disease progression. Improve compliance, capture richer evidence and cut the cost of site visits.
For pharma & research →In my current scheme, sometimes I forget that I have Parkinson's.
Koios helps me identify a patient's pains quickly and offer better care.
Sharing objective data with my doctor has improved our conversations significantly.
Peer-reviewed publications, and research conducted with hospitals across Belgium as sites of the KC-QI-2023 study.
Their listing does not indicate routine clinical use of Parkiwatch at these sites.
Backed byKoios turns everyday life with Parkinson’s into evidence that patients, clinicians and researchers can act on.